New Drug Approvals

Home » Regulatory (Page 4)

Category Archives: Regulatory

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 4,822,053 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
Follow New Drug Approvals on WordPress.com

Archives

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

World Hepatitis Day – European Medicines Agency uses regulatory tools to facilitate patient access to innovative medicines


DR ANTHONY MELVIN CRASTO Ph.D's avatarDRUG REGULATORY AFFAIRS INTERNATIONAL

25/07/2014

World Hepatitis Day – European Medicines Agency uses regulatory tools to facilitate patient access to innovative medicines

According to the World Health OrganizationExternal link icon (WHO), viral hepatitis kills 1.4 million people worldwide every year. That is as many as are killed by AIDS/HIV infections.

Viral hepatitis is caused by five different types of hepatitis viruses, hepatitis A, B, C, D and E, which can lead to the development of acute or chronic inflammation of the liver.

In Europe, hepatitis C virus (HCV) infection is a major public-health challenge. It occurs in between 0.4% and 3.5% of the population in different European Union (EU) Member States and is the most common reason for liver transplantation in the EU.

The treatment paradigm for chronic hepatitis C is currently shifting rapidly with the development of several new classes of direct-acting antivirals. These new medicines display high efficacy rates allowing patients with chronic HCV…

View original post 462 more words

Concept paper on good genomics biomarker practices


DR ANTHONY MELVIN CRASTO Ph.D's avatarDRUG REGULATORY AFFAIRS INTERNATIONAL

Document details

http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/08/WC500170682.pdf

Download documentConcept paper on good genomics biomarker practices
Reference numberEMA/CHMP/PGWP/415990/2014
Statusdraft: consultation open
First published04/08/2014
Last updated04/08/2014
Consultation start date04/08/2014
Consultation end date04/11/2014
Email address for submissionspgwpsecretariat@ema.europa.eu

Summary

Genomic data have become important to evaluate efficacy and safety of a drug for regulatory approval. As a result, genomic information has been increasingly included in drug labels relevant for the benefit/risk evaluation of a drug and consequently as guidance for patient treatment.

View original post

Europe to boost cooperation with international partners on generics


DR ANTHONY MELVIN CRASTO Ph.D's avatarDRUG REGULATORY AFFAIRS INTERNATIONAL

07/08/2014

Europe to boost cooperation with international partners on generics

European system to be used as model to facilitate assessment of medicines

The European Union’s decentralised procedure is being used as a model to accelerate the assessment of applications for generic medicines as part of theInternational Generic Drug Regulators PilotExternal link icon (IGDRP).

The European Union (EU) is leading an international pilot project through which, upon request from a generic pharmaceutical company, it will share the assessment reports generated as part of the decentralised procedure in real time with collaborating regulatory agencies outside the EU.

By offering to share its assessment reports, the EU aims to reinforce collaboration and information-sharing between regulatory authorities across the world, contributing to facilitating and strengthening the scientific assessment process for medicines. This should enable medicines to be authorised in different territories in a coordinated way at approximately the same time.

The first phase of the…

View original post 177 more words

GMP Matrix – EU GMP Guide – FDA cGMP Guide and ISO 9001 comparison


 

 

How can one find a certain GMP requirement in the EU GMP Guide, in the FDA cGMP Guide and in the ISO 9001 without searching for a long time? The Good Practice Guide developed by the ECA has become a standard in many companies and is aimed at providing this information. A 26 pages matrix provides information about where to find a GMP requirement e.g. on Validation, QC Lab testing etc in the three major Guidelines. The comprehensive booklet with 500 pages contains a full text version of all three guidelines. You can find the GMP Matrix here.

http://www.gmp-compliance.org/eca_handbuecher.html

Publications

ECA Good Practice Guide – “GMP Matrix”

“FDA cGMP, EU GMP and ISO 9001 Matrix for a pharmaceutical Quality System – A GMP Roadmap”. (Version 15 of April 2014)
The revised ECA Good Practice Guide is a comprehensive juxtaposition containing the requirements laid down in FDA’s cGMP Guide, the EU GMP Guide and ISO 9001. The updated Matrix now has 26 pages as well as further 500 pages for the following three regulations

  • FDA cGMP Guide
  • EU GMP Guide Part I, II, and III incl. all Annexes
  • ISO 9001 Quality Management Systems

In addition, the Good Practice Guide contains a ISO 9001/ICH10 Matrix and the complete Part III to the EU GMP Guide.

Price*: € 149 Non ECA Members, € 99 ECA Members

EMA publishes Document on the Validation of analytical Methods


 

 

Is it possible to use the results of collaborative trials for analytical methods to prove the laboratory- and product-specific validation of a method? From the perspective of this EMA reflection paper the concrete specifications are missing. These will be developed in the future. Find out more in this news.

http://www.gmp-compliance.org/enews_4415_EMA%20publishes%20Document%20on%20the%20Validation%20of%20analytical%20Methods_8430,8360,8369,Z-QCM_n.html

GMP News: EMA publishes Document on the Validation of analytical Methods

On 26 June 2014, the European Medicines Agency (EMA) published the concept paper “Transferring quality control methods validated in collaborative trials to a product/laboratory specific context”.

To accept a method an authority always requires a scientific validation. The same applies when existing methods are to be replaced, reduced or to be optimized (3R = replacement, reduction, refinement). Many of these new methods principally represent an improvement compared to the old “standard” methods and therefore are acceptable from a regulatory perspective.

The scientific proof of validation also includes the evidence of the concept and the possibility to transfer a method between different laboratories as well as large scale collaborative studies indicating that a method is suitable for the intended purpose. After completing these steps successfully, it can ultimately result in a monograph of the European Pharmacopoeia (Ph. Eur.) or also in a guidance document for the WHO or the EMA.

This method’s validity has to be proven by the laboratory that proposes the new method. Moreover, this validation also needs to be proven specifically for the medicinal products it is supposed to be used for. Laboratories that participated in large scale collaborative studies before, usually already created plenty of data telling something about the function of this method.

This EMA concept paper now suggests that more guidance documents should be developed on this subject: how can these data from large scale collaborative studies be used to easier implement the laboratory- and product-specific validation of 3R methods (3R – see above)? The concrete specifications for this are currently still missing.

 

The issue is also to introduce an alternative method without necessarily having to show that the new method correlates with the existing Pharmacopoeia method.

To get additional details please see the complete Reflection Paper “Transferring quality control methods validated in collaborative trials to a product/laboratory specific context“.

The deadline for submission of comments is on 31 October 2014.

 

Key steps in implementation of QbD for a biotech product…….Quality by design for biopharmaceuticals


Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

 

 

Identifying target product profile (TPP). TPP has been defined as a “prospective and dynamic summary of the quality characteristics of a drug product that ideally will be achieved to ensure that the desired quality, and thus the safety and efficacy, of a drug product is realized”. This includes dosage form and route of administration, dosage form strength(s), therapeutic moiety release or delivery and pharmacokinetic characteristics (e.g., dissolution and aerodynamic performance) appropriate to the drug product dosage form being developed and drug product-quality criteria (e.g., sterility and purity) appropriate for the intended marketed product. The concept of TPP in this form and its application is novel in the QbD paradigm.

Identifying CQAs. Once TPP has been identified, the next step is to identify the relevant CQAs. A CQA has been defined as “a physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality”10. Identification of CQAs is done through risk assessment as per the ICH guidance Q9 . Prior product knowledge, such as the accumulated laboratory, nonclinical and clinical experience with a specific product-quality attribute, is key in making these risk assessments. Such knowledge may also include relevant data from similar molecules and data from literature references. Taken together, this information provides a rationale for relating the CQA to product safety and efficacy. The outcome of the risk assessment would be a list of CQAs ranked in order of importance. Use of robust risk assessment methods for identification of CQAs is novel to the QbD paradigm.

Defining product design space. After CQAs for a product have been identified, the next step is to define the product design space (that is, specifications for in-process, drug substance and drug product attributes). These specifications are established based on several sources of information that link the attributes to the safety and efficacy of the product, including, but not limited to, the following:

  • Clinical design space
  • Nonclinical studies with the product, such as binding assays, in vivo assays and in vitro cell-based assays
  • Clinical and nonclinical studies with similar platform products
  • Published literature on other similar products
  • Process capability with respect to the variability observed in the manufactured lots

The difference between the actual experience in the clinic and the specifications set for the product would depend on our level of understanding of the impact that the CQA under consideration can have on the safety and efficacy of the product. For example, taking host cell proteins as a CQA, it is common to propose a specification that is considerably broader than the clinical experience. This is possible because of a greater ability to use data from other platform molecules to justify the broader specifications. On the other hand, in the case of an impurity that is unique to the product, the specifications would rely solely on clinical and nonclinical studies.

In QbD, an improved understanding of the linkages between the CQA and safety and efficacy of the product is required. QbD has brought a realization of the importance of the analytical, nonclinical and animal studies in establishing these linkages and has led to the creation of novel approaches.

Defining process design space. The overall approach toward process characterization involves three key steps. First, risk analysis is performed to identify parameters for process characterization. Second, studies are designed using design of experiments (DOE), such that the data are amenable for use in understanding and defining the design space. And third, the studies are executed and the results analyzed to determine the importance of the parameters as well as their role in establishing design space.

Failure mode and effects analysis (FMEA) is commonly used to assess the potential degree of risk for every operating parameter in a systematic manner and to prioritize the activities, such as experiments, necessary to understand the impact of these parameters on overall process performance. A team consisting of representatives from process development, manufacturing and other relevant disciplines performs an assessment to determine severity, occurrence and detection. The severity score measures the seriousness of a particular failure and is based on an estimate of the severity of the potential failure effect at a local or process level and the potential failure effect at end product use or patient level. Occurrence and detection scores are based on an excursion (manufacturing deviation) outside the operating range that results in the identified failure. Although the occurrence score measures how frequently the failure might occur, the detection score indicates the probability of timely detection and correction of the excursion or the probability of detection before end product use. All three scores are multiplied to provide a risk priority number (RPN) and the RPN scores are then ranked to identify the parameters with a high enough risk to merit process characterization.  FMEA outcome for a process chromatography step in a biotech process. RPN scores are calculated and operating parameters with an RPN score >50 are characterized using a qualified scaled-down model. For the case study presented here, these include gradient slope, temperature, flow rate, product loading, end of pool collection, buffer A pH, start of pool collection, volume of wash 1, buffer B pH, buffer C pH and bed height. Process characterization focused on parameters such as temperature, that have a high impact on the process (severity = 6), occur frequently in the manufacturing plant (occurrence = 6) and are difficult to quickly correct if detected (detection = 7). In contrast, parameters such as equilibration volume, with a low impact on the process (severity = 3), low occurrence (occurrence = 2) and a limited ability to detect and correct (detection = 5), were not examined in process characterization.

I liked this pic

this is the check" class="grayscale

SEE AT

http://www.tevapharm.com/Media/EventsUpdates/Pages/Quality-by-Design.aspx

IMPs: How do GDP Guidelines apply?


 

Is distribution of Investigational Medicinal Products covered by the new Guidelines on Good Distribution Practice (GDP)? What needs to be considered can be found here.

http://www.gmp-compliance.org/enews_4424_IMPs%3A%20%20How%20do%20GDP%20Guidelines%20apply%3F_8397,8527,9008,Z-PDM_n.html

 

GMP News: IMPs: How do GDP Guidelines apply?

The 2013 Guidelines on Good Distribution Practice (2013/C 343/01) apply to medicinal products for human use. Investigational Medicinal Products (IMPs) are also medicinal products for human use. But is IMP distribution really covered by the new Guidelines? The Guidelines focus on wholesale distribution of medicinal products. And IMPs are normally not distributed via wholesalers. However IMPs are not particularly excluded. The Guideline may therefore give some guidance on how to supply clinical trial material. Better guidance might be given by the Questions and Answers documents of the European Medicines Agency (EMA). In the part on supplementary requirements, Annex 13, a few Q&As are dealing with storage and transportation of IMPs.

When it comes to transport of IMPs from the manufacturer to the distributor or investigator sites, the sponsor is responsible for controlling the distribution chain and assuring “that IMPs are stored, transported, and handled in a suitable manner”. The responsibility for storage and transportation lies with the manufacturer or an importer, when the IMP comes from outside the EU. To define the specific responsibilities of the parties involved, a contract should be in place.

During storage and transportation, conditions should at least be monitored. The sponsor should define the applicable storage (and transport) conditions for the IMPs. When the IMP arrives at the investigator site, IMPs should be stored in a restricted area where appropriate, with ongoing monitoring. Everything should be defined in SOPs.

 

 

 

 

Draft USP Chapter 1223 Validation of Alternative Microbiological Methods published


 

The USP published the draft of the revised chapter 1223 “Validation of Alternative Microbiologiocal Methods.” Read more.

http://www.gmp-compliance.org/enews_4397_Draft%20USP%20Chapter%201223%20Validation%20of%20Alternative%20Microbiological%20Methods%20published_8521,8474_n.html

 

GMP News: Draft USP Chapter 1223 Validation of Alternative Microbiological Methods published

 

With the GMP News from 21. November 2012 we informed you about the status of the revision of USP chapter 1223, Validation of Alternative Microbiological Methods. Now the USP published a draft of the document.

The draft provides guidance with regard to the selection and implementation of appropriate methods, i.e. important steps for the evaluation of possible methods, for the selection of the analytical technology and finally for the qualification with regard to a current product. In this context the chapter includes information about demonstration that the new method is comparable to the compendial method, and about applicability as a replacement for an existing method. Furthermore the document provides information about the qualification of a method in the laboratory.

The public can provide comments on the draft chapter 1223 until September 30, 2014. The draft chapter can be found at USP website. You are required to register to gain access to the USP PF online, but this is a free service to the pharmaceutical community.

 

 

  • PDA Microbiology Conference Update: Revision of USP 1223

    blog.rapidmicromethods.com/2012/…/usp-chapter1223-validation-of.ht…

    Oct 23, 2012 – USP Chapter 1223, Validation of Alternative Microbiological Methods, has been under revision for at least the past year. During today’s …

  • GMP News: Revision of USP 1223 – current Status

    GMP News 21/11/2012. Revision of USP 1223 – current Status. The chapter <1223> Validation of Alternative Microbiological Methods of the USP is still under …

  • GMP News: Draft USP Chapter 1223 Validation of

    17 hours ago – November 2012 we informed you about the status of the revision of USPchapter 1223, Validation of Alternative Microbiological Methods.

    1223 VALIDATION OF ALTERNATIVE MICROBIOLOGICAL METHODS

    INTRODUCTION
    The purpose of this chapter is to provide guidance for validating methods for use as alternatives to the official compendial microbiological methods. For microbial recovery and identification, microbiological testing laboratories sometimes use alternative test methods to those described in the general chapters for a variety of reasons, such as economics, throughput, and convenience. Validation of these methods is required. Some guidance on validation of the use of alternate methods is provided in the Tests and Assays section in the General Notices and Requirements. This section also notes that in the event of a dispute, only the result obtained by the compendial test is conclusive.
    Validation studies of alternate microbiological methods should take a large degree of variability into account. When conducting microbiological testing by conventional plate count, for example, one frequently encounters a range of results that is broader (%RSD 15 to 35) than ranges in commonly used chemical assays (%RSD 1 to 3). Many conventional microbiological methods are subject to sampling error, dilution error, plating error, incubation error, and operator error.
    Validation of Compendial Procedures 1225 defines characteristics such as accuracy, precision, specificity, detection limit, quantification limit, linearity, range, ruggedness, and robustness in their application to analytical methods. These definitions are less appropriate for alternate microbiological method validation as “at least equivalent to the compendial method” given the comparative nature of the question (see the Tests and Assays—Procedures section in General Notices and Requirements). The critical question is whether or not the alternate method will yield results equivalent to, or better than, the results generated by the conventional method.
    Other industry organizations have provided guidance for the validation of alternate microbiological methods.* The suitability of a new or modified method should be demonstrated in a comparison study between the USP compendial method and the alternate method. The characteristics defined in this chapter may be used to establish this comparison.

    TYPES OF MICROBIOLOGICAL TESTS
    It is critical to the validation effort to identify the portion of the test addressed by an alternate technology. For example, there is a variety of technologies available to detect the presence of viable cells. These techniques may have application in a variety of tests (e.g., bioburden, sterility test) but may not, in fact, replace the critical aspects of the test entirely. For example, a sterility test by membrane filtration may be performed according to the compendial procedure up to the point of combining the processed filter with the recovery media, and after that the presence of viable cells might then be demonstrated by use of some of the available technologies. Validation of this application would, therefore, require validation of the recovery system employed rather than the entire test.
    There are three major types of determinations specific to microbiological tests. These include tests to determine whether microorganisms are present in a sample, tests to quantify the number of microorganisms (or to enumerate a specific subpopulation of the sample), and tests designed to identify microorganisms. This chapter does not address microbial identification.
    Qualitative Tests for the Presence or Absence of Microorganisms
    This type of test is characterized by the use of turbidity in a liquid growth medium as evidence of the presence of viable microorganisms in the test sample. The most common example of this test is the sterility test. Other examples of this type of testing are those tests designed to evaluate the presence or absence of a particular type of microorganism in a sample (e.g., coliforms in potable water and E. coli in oral dosage forms).
    Quantitative Tests for Microorganisms
    The plate count method is the most common example of this class of tests used to estimate the number of viable microorganisms present in a sample. The membrane filtration and Most Probable Number (MPN) multiple-tube methods are other examples of these tests. The latter was developed as a means to estimate the number of viable microorganisms present in a sample not amenable to direct plating or membrane filtration.
    General Concerns
    Validation of a microbiological method is the process by which it is experimentally established that the performance characteristics of the method meet the requirements for the intended application, in comparison to the traditional method. For example, it may not be necessary to fully validate the equivalence of a new quantitative method for use in the antimicrobial efficacy test by comparative studies, as the critical comparison is between the new method of enumeration and the plate count method (the current method for enumeration). As quantitative tests, by their nature, yield numerical data, they allow for the use of parametric statistical techniques. In contrast, qualitative microbial assays, e.g., the sterility test in the example above, may require analysis by nonparametric statistical methods. The validation of analytical methods for chemical assays follows well-established parameters as described in Validation of Compendial Procedures 1225. Validation of microbiological methods shares some of the same concerns, although consideration must be given to the unique nature of microbiological assays (see Table 1).
    Table 1. Validation Parameters by Type of Microbiological Test
    Parameter Qualitative
    Tests
    Quantitative
    Tests
    Accuracy No Yes
    Precision No Yes
    Specificity Yes Yes
    Detection limit Yes Yes
    Quantification limit No Yes
    Linearity No Yes
    Operational range No Yes
    Robustness Yes Yes
    Repeatability Yes Yes
    Ruggedness Yes Yes

    VALIDATION OF QUALITATIVE TESTS FOR DEMONSTRATION OF VIABLE MICROORGANISMS IN A SAMPLE
    Specificity
    The specificity of an alternate qualitative microbiological method is its ability to detect a range of microorganisms that may be present in the test article. This concern is adequately addressed by growth promotion of the media for qualitative methods that rely upon growth to demonstrate presence or absence of microorganisms. However, for those methods that do not require growth as an indicator of microbial presence, the specificity of the assay for microbes assures that extraneous matter in the test system does not interfere with the test.
    Limit of Detection
    The limit of detection is the lowest number of microorganisms in a sample that can be detected under the stated experimental conditions. A microbiological limit test determines the presence or absence of microorganisms, e.g., absence of Salmonella spp. in 10 g. Due to the nature of microbiology, the limit of detection refers to the number of organisms present in the original sample before any dilution or incubation steps; it does not refer to the number of organisms present at the point of assay.
    One method to demonstrate the limit of detection for a quantitative assay would be to evaluate the two methods (alternative and compendial) by inoculation with a low number of challenge microorganisms (not more than 5 cfu per unit) followed by a measurement of recovery. The level of inoculation should be adjusted until at least 50% of the samples show growth in the compendial test. It is necessary to repeat this determination several times, as the limit of detection of an assay is determined from a number of replicates (not less than 5). The ability of the two methods to detect the presence of low numbers of microorganisms can be demonstrated using the Chi square test. A second method to demonstrate equivalence between the two quantitative methods could be through the use of the Most Probable Number technique. In this method, a 5-tube design in a ten-fold dilution series could be used for both methods. These would then be challenged with equivalent inoculums (for example, a 10–1, 10–2, and 10–3 dilution from a stock suspension of approximately 50 cfu per mL to yield target inocula of 5, 0.5, and 0.05 cfu per tube) and the MPN of the original stock determined by each method. If the 95% confidence intervals overlapped, then the methods would be considered equivalent.
    Ruggedness
    The ruggedness of a qualitative microbiological method is the degree of precision of test results obtained by analysis of the same samples under a variety of normal test conditions, such as different analysts, instruments, reagent lots, and laboratories. Ruggedness can be defined as the intrinsic resistance to the influences exerted by operational and environmental variables on the results of the microbiological method. Ruggedness is a validation parameter best suited to determination by the supplier of the test method who has easy access to multiple instruments and batches of components.
    Robustness
    The robustness of a qualitative microbiological method is a measure of its capacity to remain unaffected by small but deliberate variations in method parameters, and provides an indication of its reliability during normal usage. Robustness is a validation parameter best suited to determination by the supplier of the test method. As there are no agreed upon standards for current methods, acceptance criteria are problematic and must be tailored to the specific technique. It is essential, however, that an estimate of the ruggedness of the alternate procedure be developed. The measure of robustness is not necessarily a comparison between the alternate method and the traditional, but rather a necessary component of validation of the alternate method so that the user knows the operating parameters of the method.

    VALIDATION OF QUANTITATIVE ESTIMATION OF VIABLE MICROORGANISMS IN A SAMPLE
    As colony-forming units follow a Poisson distribution, the use of statistical tools appropriate to the Poisson rather than those used to analyze normal distributions is encouraged. If the user is more comfortable using tools geared towards normally distributed data, the use of a data transformation is frequently useful. Two techniques are available and convenient for microbiological data. Raw counts can be transformed to normally distributed data either by taking the log10 unit value for that count, or by taking the square root of count +1. The latter transformation is especially helpful if the data contain zero counts.
    Accuracy
    The accuracy of this type of microbiological method is the closeness of the test results obtained by the alternate test method to the value obtained by the traditional method. It should be demonstrated across the operational range of the test. Accuracy is usually expressed as the percentage of recovery of microorganisms by the assay method.
    Accuracy in a quantitative microbiological test may be shown by preparing a suspension of microorganisms at the upper end of the range of the test, that has been serially diluted down to the lower end of the range of the test. The operational range of the alternate method should overlap that of the traditional method. For example, if the alternate method is meant to replace the traditional plate count method for viable counts, then a reasonable range might be from 100 to 106 cfu per mL. At least 5 suspensions across the range of the test should be analyzed for each challenge organism. The alternate method should provide an estimate of viable microorganisms not less than 70% of the estimate provided by the traditional method, or the new method should be shown to recover at least as many organisms as the traditional method by appropriate statistical analysis, an example being an ANOVA analysis of the log10 unit transforms of the data points. Note that the possibility exists that an alternate method may recover an apparent higher number of microorganisms if it is not dependent on the growth of the microorganisms to form colonies or develop turbidity. This is determined in the Specificity evaluation.
    Precision
    The precision of a quantitative microbiological method is the degree of agreement among individual test results when the procedure is applied repeatedly to multiple samplings of suspensions of laboratory microorganisms across the range of the test. The precision of a microbiological method is usually expressed as the standard deviation or relative standard deviation (coefficient of variation). However, other appropriate measures may be applied.
    One method to demonstrate precision uses a suspension of microorganisms at the upper end of the range of the test that has been serially diluted down to the lower end of the range of the test. At least 5 suspensions across the range of the test should be analyzed. For each suspension at least 10 replicates should be assayed in order to be able to calculate statistically significant estimates of the standard deviation or relative standard deviation (coefficient of variation). Generally, a RSD in the 15% to 35% range would be acceptable. Irrespective of the specific results, the alternate method should have a coefficient of variation that is not larger than that of the traditional method. For example, a plate count method might have the RSD ranges as shown in the following table.
    Table 2. Expected RSD as a Function of cfu per Plate
    cfu per Plate Expected RSD
    30–300 <15%
    10–30 <25%
    <10 <35%
    Specificity
    The specificity of a quantitative microbiological method is its ability to detect a panel of microorganisms suitable to demonstrate that the method is fit for its intended purpose. This is demonstrated using the organisms appropriate for the purpose of the alternate method. It is important to challenge the alternate technology in a manner that would encourage false positive results (specific to that alternate technology) to demonstrate the suitability of the alternate method in comparison to the traditional method. This is especially important with those alternate methods that do not require growth for microbial enumeration (for example, any that do not require enrichment or can enumerate microorganisms into the range of 1–50 cells).
    Limit of Quantification
    The limit of quantification is the lowest number of microorganisms that can be accurately counted. As it is not possible to obtain a reliable sample containing a known number of microorganisms, it is essential that the limit of quantification of an assay is determined from a number of replicates (n > 5) at each of at least 5 different points across the operational range of the assay. The limit of quantification should not be a number greater than that of the traditional method. Note that this may have an inherent limit due to the nature of bacterial enumeration and the Poisson distribution of bacterial counts (see Validation of Microbial Recovery from Pharmacopeial Articles 1227). Therefore, the alternate method need only demonstrate that it is at least as sensitive as the traditional method to similar lower limits.
    Linearity
    The linearity of a quantitative microbiological test is its ability to produce results that are proportional to the concentration of microorganisms present in the sample within a given range. The linearity should be determined over the range of the test. A method to determine this would be to select at least 5 concentrations of each standard challenge microorganism and conduct at least 5 replicate readings of each concentration. An appropriate measure would be to calculate the square of the correlation coefficient, r2, from a linear regression analysis of the data generated above. While the correlation coefficient does not provide an estimate of linearity, it is a convenient and commonly applied measure to approximate the relationship. The alternate method should not have an r2 value less than 0.95.
    Limit of Detection
    See Limit of Detection under Validation of Qualitative Tests for Demonstration of Viable Microorganisms in a Sample.
    Range
    The operational range of a quantitative microbiological method is the interval between the upper and lower levels of microorganisms that have been demonstrated to be determined with precision, accuracy, and linearity.
    Ruggedness
    See Ruggedness under Validation of Qualitative Tests for Demonstration of Viable Microorganisms in a Sample.
    Robustness
    See Robustness under Validation of Qualitative Tests for Demonstration of Viable Microorganisms in a Sample.

    *  PDA Technical Report No. 33. The Evaluation, Validation and Implementation of New Microbiological Testing Methods. PDA Journal of Pharmaceutical Science & Technology. 54 Supplement TR#33 (3) 2000 and Official Methods Programs of AOAC International.

 

 

 

European Pharmacopoeia Commission announces Strategy for Implementation of ICH Q3D


The publication of the final ICH Q3D guideline, which has been announced for September of this year, will lead to extensive revisions to chapters and monographs in the European Pharmacopoeia. Find out in what steps the Pharmacopoeia Commission will proceed.

http://www.gmp-compliance.org/enews_4418_European%20Pharmacopoeia%20Commission%20announces%20Strategy%20for%20Implementation%20of%20ICH%20Q3D_8559,S-AYL_n.html

GMP News: European Pharmacopoeia Commission announces Strategy for Implementation of ICH Q3D

In a press release from 7 July 2014, the ICH Steering Committee announced that the finalisation of the ICH Q3D Guideline on Elemental Impurities is planned for September 2014. A press release of the European Pharmacopoeia Commission entitled “The European Pharmacopoeia Commission validates its strategy regarding elemental impurities and the implementation plan of the upcoming ICH Q3D guideline” was released 11 days later. In this release, the Commission explains their approach with regard to the integration of the content of ICH Q3D in the European Pharmacopoeia. This is supposed to be done in the following steps:

  • Chapter 5.20 of the Pharmacopoeia (“Metal catalysts or metal reagent residues”), which so far includes a literal rendition of the EMA Guideline “Specification limits for residues of metal catalysts or metal reagents“, will be replaced by the wording of the ICH Q3D Guideline, as soon as it is published as Step 4 document.
  • Chapter 5.20 will only become legally binding when it is referenced in a pharmacopoeia monograph. For this purpose references to Chapter 5.20 are supposed to be inserted in the general monographs 2034 (“Substances for pharmaceutical use’) and 2619 (“Pharmaceutical preparations”). The time at which this will take place, has not yet been fixed and depends on the CHMP, which must formally decide to replace the EMA guideline by ICH Q3D in Chapter 5.20.
  • In all individual monographs (except in those that relate to substances for veterinary medicinal products) references to Chapter 2.4.8 will be removed. This Chapter still describes wet chemical tests for heavy metals. A list of the affected monographs will appear in the January 2015 issue of the journal “Pharmeuropa”. The publication of the revised monographs is intended for the 9th edition of the European Pharmacopoeia with an implementation date of 1 January 2017.
    • Chapter 2.4.20 (“Determination of metal catalyst and metal reagent residues”) covering the topics of “sample preparation” and “method suitability”, will be reviewed and adapted to the requirements according to ICH Q3D.

    After the revision of the individual chapters and monographs it is at the discretion of the responsible quality control laboratories to choose an appropriate analytical strategy in accordance with the requirements of ICH Q3D.

 

………………..

clippings

 

  • Draft Document:
    July 2013

    Description:

    The Q3D draft Guideline has been relased for consultation under Step 2B of the ICH process in July 2013.

    This new guidance is proposed to provide a global policy for limiting metal impurities qualitatively and quantitatively in drug products and ingredients. The existing ICH Q3A Guideline classifies impurities as organic, inorganic, and residual solvents. The Q3A and Q3B Guidelines effectively address the requirements for organic impurities. An additional Guideline Q3C was developed to provide clarification of the requirements for residual solvents. The proposed new Guideline Q3D would provide similar clarification of the requirements for metals, which are included in the ICH inorganic impurities classification.

     

    Status:

    Step 2b

    EU:

    Transmission to CHMP in June 2013, issued as EMA/CHMP/ICH/353369/2013. Deadline for comments: 31 December 2013

    MHLW:

    Released for consultation, 4 October 2013, PFSB/ELD. Deadline for comments: 29 November 2013

    FDA:

    Published in the Federal Register 23 October 2013, Vol. 78, No. 205, p. 63219-20. Deadline for comments: 23 December 2013

………………………….

Q3D Elemental Impurities – Food and Drug Administration

Sep 30, 2013 – This document reached step 2B of the ICH Process on June 6, 2013. For questions … Q3D. Approval by the Steering Committee under Step 2b

 

………………

Guideline for Elemental Impurities – ICH

www.ich.org/fileadmin/Public_Web…/ICH…/Q3D/Q3D_Step2b.pdf

DRAFT CONSENSUS GUIDELINE. GUIDELINE FOR ELEMENTAL IMPURITIES. Q3D. Current Step 2b version dated 26 July 2013. At Step 2 of the ICH Process, …

………………………………………………
ICH Q3D Guideline reaches Step 2b of the ICH Process

5 August 2013

The ICH Q3D Guideline for Elemental Impurities reached Step 2b of the ICH Process in July 2013 and now enters the consultation period (Step 3).

This new Guideline is proposed to provide a global policy for limiting metal impurities qualitatively and quantitatively in drug products and ingredients. The existing ICH Q3A Guideline classifies impurities as organic, inorganic, and residual solvents. The Q3A and Q3B Guidelines effectively address the requirements for organic impurities.
An additional Guideline Q3C was developed to provide clarification of the requirements for residual solvents.
The proposed new Guideline Q3D would provide similar clarification of the requirements for metals, which are included in the ICH inorganic impurities classification.

The draft Guideline is now available for download under the Quality Guideline page. ローテンシルト通販ニクソン腕時計You are invited to provide comments on the draft Guideline by e-mailing the ICH Secretariat. More details under the Open Consultation page.

Note that stakeholders from EU, US and Japan are encouraged to submit their comments to their respective Regulatory Authorities.

Water Systems in FDA Warning Letters


 

Among the FDA Warning Letters of the past two years there are every now and then letters citing deficiencies in water systems. On the bottom line the reason for objections is always the same. Read more.

 

http://www.gmp-compliance.org/enews_4359_Water%20Systems%20in%20FDA%20Warning%20Letters_8398,8427,8428,Z-PEM_n.html

GMP News: Water Systems in FDA Warning Letters

Taking a look at FDA Warning Letters from the past two years, objections with regard to pharmaceutical water systems are rather seldom. However, when there are complaints, it is the more interesting that the reason for these complaints is mostly the same: missing reliability. What the authority means in this case is the proof that the water system is capable of securely and reliably producing water in the required quality – taking into account for example the fluctuations in the feed water. The necessary means for this purpose are the validation of the water system and the establishment of a monitoring system which continuously verifies the function.

Excerpts from Warning Letters:

1. Failure to validate and monitor the water purification system to ensure that water is of appropriate quality. […]  In your response to the observations noted during the 2012 inspection, you indicated your firm’s intention to conduct a comprehensive gap analysis of the purified water system. However, you have failed to indicate when you will initiate this gap analysis and when it will be completed. Your firm also failed to detail how you will determine the source(s) of high endotoxin and TOC in your purified water and how your firm will remedy identified problem(s). We note that, for example, your firm installed an endotoxin removal unit on your purified water system in January 2011 in response to the OOS results for endotoxin in the water used for API. However, your firm has not demonstrated that the water produced by the purified water system is now suitable for use in production. The operational parameters and effectiveness of the new endotoxin removal unit have not been qualified. Your firm does not monitor the microbial and chemical attributes of the feed water, and have no assurances that the purified water system is capable of consistently producing water that meets specifications for a given quality of feed water.

2. Your firm failed to assure that your water system is suitably designed and operated to produce appropriate water quality. Regarding the latter, your firm has not established and validated appropriate cleaning and sanitizing schedules for your purified water system. You have hired a water process subject matter expert and taken other steps to strengthen monitoring of the purified water system. Your response is not acceptable because you have not demonstrated that your purified water system is capable of operating in a continuing state of control.

3. […] your firm failed to subject the water to routine microbiological testing. Furthermore, your firm failed to validate the water system to ensure consistent water quality for drug production and implement procedures for maintaining or monitoring the quality of the water produced.